S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:TNYA

Tenaya Therapeutics (TNYA) Stock Price, News & Analysis

$5.16
+0.33 (+6.83%)
(As of 03/27/2024 ET)
Today's Range
$4.75
$5.29
50-Day Range
$3.19
$6.80
52-Week Range
$1.66
$8.09
Volume
621,466 shs
Average Volume
633,545 shs
Market Capitalization
$405.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.40

Tenaya Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
198.4% Upside
$15.40 Price Target
Short Interest
Healthy
4.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of Tenaya Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.68) to ($1.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

318th out of 939 stocks

Biological Products, Except Diagnostic Industry

46th out of 151 stocks

TNYA stock logo

About Tenaya Therapeutics Stock (NASDAQ:TNYA)

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

TNYA Stock Price History

TNYA Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Tenaya Therapeutics (NASDAQ:TNYA) Price Target Cut to $18.00
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
TNYA Mar 2024 7.500 put
TNYA Apr 2024 7.500 put
Tenaya Announces Pricing Of $50 Mln Underwritten Offering; Stock Up
See More Headlines
Receive TNYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/27/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TNYA
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.40
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+198.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-124,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.05 per share

Miscellaneous

Free Float
51,954,000
Market Cap
$405.16 million
Optionable
Optionable
Beta
2.65
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Faraz Ali M.B.A. (Age 51)
    CEO, Secretary & Director
    Comp: $816.39k
  • Dr. Deepak Srivastava M.D. (Age 58)
    Scientific Founder, Chairman of Scientific Advisory Board & Director
    Comp: $118k
  • Dr. Timothy Hoey Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $573k
  • Dr. Whittemore G. Tingley M.D. (Age 56)
    PH.D., Chief Medical Officer
    Comp: $621.98k
  • Dr. Eric N. Olson Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Dr. Bruce R. Conklin
    Scientific Founder
  • Dr. Saptarsi Haldar M.D.
    Scientific Founder
  • Dr. Sheng Ding Ph.D.
    Scientific Founder
  • Dr. Benoit G. Bruneau Ph.D.
    Scientific Founder
  • Ms. Leone D. Patterson M.B.A. (Age 62)
    Chief Financial & Business Officer
    Comp: $448.55k

TNYA Stock Analysis - Frequently Asked Questions

Should I buy or sell Tenaya Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNYA shares.
View TNYA analyst ratings
or view top-rated stocks.

What is Tenaya Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 12-month price targets for Tenaya Therapeutics' stock. Their TNYA share price targets range from $7.00 to $20.00. On average, they expect the company's stock price to reach $15.40 in the next year. This suggests a possible upside of 198.4% from the stock's current price.
View analysts price targets for TNYA
or view top-rated stocks among Wall Street analysts.

How have TNYA shares performed in 2024?

Tenaya Therapeutics' stock was trading at $3.24 at the beginning of the year. Since then, TNYA stock has increased by 59.3% and is now trading at $5.16.
View the best growth stocks for 2024 here
.

When is Tenaya Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TNYA earnings forecast
.

How were Tenaya Therapeutics' earnings last quarter?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.20.

When did Tenaya Therapeutics IPO?

Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

Who are Tenaya Therapeutics' major shareholders?

Tenaya Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.67%), Price T Rowe Associates Inc. MD (6.67%), Vanguard Group Inc. (3.61%), Vanguard Group Inc. (3.61%), GSA Capital Partners LLP (0.69%) and Northern Trust Corp (0.57%). Insiders that own company stock include David V Goeddel, Deepak Srivastava, Eli Casdin, Faraz Ali, Group Gp Lp Column III and Timothy Hoey.
View institutional ownership trends
.

How do I buy shares of Tenaya Therapeutics?

Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNYA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners